NovoCure (NVCR) Gross Margin (2014 - 2026)

NovoCure has disclosed Gross Margin across 13 years of filings, most recently posting 77.63% for Q1 2026.

• Gross Margin for Q1 2026 came in at 77.63%, up 249.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 75.2% (down 196.0% YoY), and the FY2025 annual result was 74.54%, down 280.0% from the prior year.
• Gross Margin came in at 77.63% for Q1 2026 at NovoCure, up from 75.82% in the prior quarter.
• In the past five years, Gross Margin ranged from a high of 79.84% in Q1 2022 to a low of 73.01% in Q2 2023.
• The 5-year median for Gross Margin is 75.82% (2025), against an average of 76.38%.
• Across the five-year window, Gross Margin slumped 675 bps in 2023 and soared 394 bps in 2024, its largest moves.
• NovoCure's Gross Margin stood at 77.51% in 2022, then retreated by 2 bps to 75.67% in 2023, then increased by 5 bps to 79.25% in 2024, then slipped by 4 bps to 75.82% in 2025, then advanced by 2 bps to 77.63% in 2026.
• The last three Gross Margin figures came in at 77.63% (Q1 2026), 75.82% (Q4 2025), and 73.25% (Q3 2025), per Business Quant data.